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Abstract 
Particle therapy is a growing cancer treatment modality worldwide. However, there still remains a 
number of unanswered questions considering differences in the biological response between particles 
and photons. These questions, and probing of biological mechanisms in general, necessitate 
experimental investigation. The “Infrastructure in Proton International Research” (INSPIRE) project 
was created to provide an infrastructure for European research, unify research efforts on the topic of 
proton and ion therapy across Europe, and to facilitate the sharing of information and resources. This 
work highlights the radiobiological capabilities of the INSPIRE partners, providing details of physics 
(available particle types and energies), biology (sample preparation and post-irradiation analysis), 
and researcher access (the process of applying for beam time). The collection of information reported 
here is designed to provide researchers both in Europe and worldwide with the tools required to 
select the optimal center for their research needs. We also highlight areas of redundancy in 
capabilities and suggest areas for future investment. 
1 Introduction 
There is a growing investment in proton and heavy ion therapy worldwide, with 89 proton 
centers and 12 carbon centers currently in clinical operation (according to the Particle Therapy Co-
Operation Group (PTCOG) [1]. Of these worldwide facilities, 31 proton centers (~35%) and four 
carbon centers (~33%) are located in Europe [2]. Despite the increasing adoption of particle therapy 
there remains a number of unanswered questions about this relatively new treatment modality [3]. 
These questions range widely in scope and include physical (e.g. range uncertainties or organ motion), 
biological (e.g. uncertainties in relative biological effectiveness and lack of clinically relevant in vivo 
data), and societal aspects (e.g. cost-effectiveness and radiotherapy demand) [4]. Many clinical centers 
offer beam time for research activities to address some of these questions [5]. However, access and 
utilization of this beam time can be difficult due to a lack of supply and/or funding. Rectifying this 
situation requires targeted efforts from both researchers and funders alike. 
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The European project “Infrastructure in Proton International Research” (INSPIRE) was created to 
allow researchers across Europe access to “state-of-the-art” research capabilities in centers for proton 
therapy. In addition, multi-ion research centers (KVI, Groningen, the Netherlands; GSI, Darmstadt, 
Germany) augment the particle research portfolio. INSPIRE aims to integrate research activities in 
protons (and heavy ions) across Europe through eight objectives: 
 
1) Developing new infrastructure by bringing together clinical, academic, and industrial research 
activities. 
2) Enabling access to research infrastructure for researchers in both the public and private sector. 
3) Providing training for the next generation of researchers in the field. 
4) Facilitating knowledge exchange to promote best research practices throughout Europe. 
5) Developing joint research activities (JRAs) that will improve the facilities available within the 
infrastructure. 
6) Developing JRAs in fields where technological challenges exist to improve European 
competitiveness. 
7) Developing an innovation pipeline to translate research into clinical practice and industrial 
products. 
8) To conduct research within the principles of responsible research and innovation. 
 
The project is comprised of 17 European partners, 12 of which offer beam time through 
transnational access (TNA) (Table 1); a complete list of the INSPIRE partners can be found at 
https://protonsinspire.eu/. Further to the partners discussed in this work, the University of Namur 
(Belgium) is also an INSPIRE partner taking part in radiobiological research, but with their nearby 
partner center under development does not offer TNA through INSPIRE. However, once operational 
their resources will be available outside of the current INSPIRE project. Most of these partners are 
either clinical centers or have very close connections to clinical centers (Figure 1), for example the 
radiobiological capabilities of CHRISTIE and UNIMAN are shared as are those of RUG and UMCG. 
A close clinical link is essential to aid the design of the research at inception and to ensure its relevance 
and future translation to the clinic. 
Further to the information hosted by each institute’s website, and the information presented in 
this work, the following references give more information and available setups for Institut Curie [6–
8], TUD [9–16], IFJ PAN [17], RUG [18–24], and GSI [25–31]. 
Through INSPIRE we are able to investigate important research questions together and benefit 
from cross-validation. An immediate example is the variability in data for proton relative biological 
effectiveness (RBE) that has been seen in the literature over the years [32–35]. A coordinated effort 
amongst the INSPIRE partners is allowing this variability to be investigated both computationally and 
experimentally, and the results made available to researchers across Europe through INSPIRE’s 
experimental and modelling JRA. This systematic and coordinated approach will highlight factors 
leading to variation and propose mitigation strategies for future studies. These mitigation strategies 
will help to develop best practices for proton radiobiology research and build upon previous work on 
the topic [36]. Alongside coordinated research INSPIRE also seeks to improve the infrastructure 
available to European researchers through its TNA. Many research centers have invested significantly 
to develop their research, constructing accelerators, beamlines, and purchasing experimental 
equipment. INSPIRE also continually upgrades its research capabilities by taking research developed 
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through JRA and making it available to the wider research community via TNA. This means that 
INSPIRE is able to offer the very latest technology and capabilities.  
 TNA provides researchers an opportunity to access beam time and funding for experiments at 
INSPIRE partners. The beam time is offered to all researchers and is not limited to INSPIRE partners. 
Furthermore, whilst the beam time is largely accessible for European researchers, up to 30% of the 
hours are available to researchers outside the EU. The application process is managed through the 
INSPIRE website (https://protonsinspire.eu). Prior to submitting the application through the online 
form, the researchers are advised to contact the representative of the relevant partner site to discuss the 
technical details of their proposed experiment. Before being transferred to an independent international 
user selection panel (USP), the refined application, submitted via the online form, is first assessed to 
ensure that the requested TNA site has the capacity and infrastructure to perform the experiment. 
Afterwards, the application is evaluated by at least two members of the USP for its technical and 
scientific excellence, as well as future potential and impact. Priority is given to users who have not had 
access to the TNA before. The INSPIRE website contains details about each center, links to websites, 
and contact information for general enquiries aimed to aid the potential researcher. 
 The information provided in this paper acts as a corollary to the INSPIRE website, where up-
to-date information is maintained. Here, we provide details of the TNA radiobiology capabilities of 
each INSPIRE partner. Similar information, at least in terms of the physics capabilities, has 
previously been presented by the European Particle Therapy Network [37] and can be used alongside 
this work. Planning of a radiobiological experiment requires the knowledge of not only the beamline 
for the sample irradiation, but also of the available equipment and capabilities of the biological 
laboratories on site. The latter are essential for the sample preparation and post-processing. In this 
work, we aim to provide comprehensive information on the facilities available across INSPIRE. We 
specify details of the “physics”, including location, beamlines, particle types, energies, and field 
sizes. We specify details of the “logistics”, including details of sample types, positioning, and 
automation. We specify details of the “biology”, including the available equipment for sample 
preparation and post-irradiation processing. Finally, we discuss future perspectives for ongoing 
development and further investment. The details provided here act as a resource for the potential 
researcher to select the optimal center for their experimental needs. However, it should be noted that 
there is often flexibility in many of the aspects we report. As such the information we provide should 
be used as a guide and more specific details can be obtained through communication with a specific 
partner or through INSPIRE’s help desk. It is apparent that the capabilities, at least in terms of 
“physics”, between many partners are similar. This level of redundancy is desirable, enabling 
repetition to ensure scientific rigor, however, establishing these centers requires a large investment 
and through INSPIRE they are able to work effectively together to ensure optimum utilization 
2 Physics – Location, Beamlines, Particles, Energies, and Fields 
A researcher often faces large heterogeneity when performing experiments between centers, 
with differences in protocol, setup, irradiation, and sample processing. Despite this there are a number 
of overlaps in beam properties and possible experiments between centers. Figure 2 shows a summary 
of capabilities for the INSPIRE TNA partners. 
TNA providers mainly cover central and northern Europe, with a similar distribution to clinical 
centers (Figure 1). Geographic positioning of centers is an important factor to minimize both travel 
expenses and logistics. A new initiative with the South East European International Institute for 
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Sustainable Technologies (SEEIST) [38,39] aims to enable researchers from the south east of Europe 
to access INSPIRE’s capabilities while they are developing their own facilities.   
All of the TNA providers can supply protons, with two centers, GSI and RUG, additionally 
offering other ion types of clinical interest, such as carbon, helium, or oxygen. As can be seen from 
Figure 3, in general, the energies available from the accelerator are similar between providers. The 
most overlapping energy region is between 120 and 190 MeV – experiments at this energy can be done 
at all of the partner centers. The highest possible energies can be achieved at GSI, reaching up to 1 
GeV/u for heavy ions and 4.5 GeV/u for protons, with relevance to proton radiography [40] 
experiments, while most of the other institutes are limited to a maximum of 230-240 MeV/u. The 
lowest possible proton energies are offered at RUG (15 MeV) and Institut Curie (20 MeV). Energies 
can be further degraded before the sample to investigate increased proton linear energy transfer, with 
a relevance for end of range effects. Access to even lower energies can be obtained through the EU 
project RADIATE [41]. 
Eight TNA providers have a dedicated research room. This can be useful for studies that require 
longer irradiations and/or longer follow-up, it also gives more freedom to experiments that require a 
complex or non-standard sample setup. However, the cost of such studies should always be considered. 
Whilst the sample may be able to remain in the room post-irradiation this will often inactivate the room 
using valuable resources. A shared room has the downside of limited usage, due to clinical 
commitments, although it has the added benefit of rigorous quality assurance to a clinical standard. 
However, it should be noted that all partners undertake measures to ensure dosimetry and quality of 
beam delivery in their research rooms. 
Figure 4 shows examples of beamlines for the CHRISTIE + UNIMAN, Skandion, RUG, TUD, 
GSI, and Institut Curie partners. 
There is a range of maximum available scanned field sizes across the INSPIRE partners, shown 
in Figure 5. Six partners, PSI, Skandion, NPI-CAS, IFJ PAN, Au, and Institut Curie, offer the same 
field size (30 × 40 cm2). TUD and CHRISTIE + UNIMAN offer the same field size but in the landscape 
orientation (40 × 30 cm2). All partners offer a field size large enough to irradiate most in vitro sample 
types, such as tissue culture flasks or microplates. The field size may become a limitation for larger 
non-standard samples, or simultaneous irradiation of multiple samples. Though in some cases the field 
size may be increased by introducing scatterers. 
Choice of reference radiation is an important aspect in general for radiobiology. The biological 
effects of protons are often quoted relative to the more familiar photon case, most notably the relative 
biological effectiveness for cell kill. A variety of reference photon qualities are used between the 
INSPIRE partners. Several partners have the possibility to choose between clinical LINACs and 
kilovoltage X-ray machines (CHRISTIE + UNIMAN, TUD, NPI-CAS, Institut Curie, RUG + 
UMCG), whilst the capabilities of others are more limited. The difference in reference radiation may 
lead to slight differences in relative effect measurements, making inter-center comparisons more 
complicated. However, it should be noted that this is a problem for radiobiology in general and is not 
limited to INSPIRE partners [42]. 
3 Logistics – Samples, Positioning, and Automation 
The mode of sample irradiation is an important consideration, including sample orientation and 
possibility of automated handling. Monolayers of cells, grown in a flask or microplate, should not be 
free from media for a long duration of time to avoid drying. As such, several centers, particularly with 
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horizontal beamlines, employ automated sample handling. Here, the sample can remain in a horizontal 
orientation and is lifted up only when presented to the beam for irradiation. Automated sample handling 
also has the added benefits of improving repeatability and minimizing access to the irradiation room, 
increasing sample throughput. Four centers employ automated sample handling. All the centers have 
the capability of a horizontal beamline, though four can additionally offer a vertical beam direction, 
and six offer more irradiating angles by using gantries. The sample type that can be irradiated is a 
limitation defined by the system. Most centers have flexibility here, with all capable of irradiating at 
least flasks and well plates. The sample type capability may go beyond this (as long as it can be fixed 
in front of the beam and meet the safety regulations of the experimental room) and should be further 
discussed with the partner institute. Table 2 shows a summary of these details. 
Figure 6 shows examples of sample presentation to the beam at Christie + UNIMAN, RUG, 
Institut Curie, GSI, and AU. The system at CHRISTIE + UNIMAN (Figure 6A) employs a 6-axis robot 
mounted inside a hypoxia end station. The space limitations of the hypoxia cabinet mean that at most 
a mix of up to 36 samples can be housed at a time. The fingers of the robot are designed for T75 flasks 
or 96-well plates, limiting the sample type. However, other samples can be used so long as they have 
the same footprint as a 96-well plate or through use of customized sample holders, alternatively a large 
range of samples can be used without the robot. Similar to the CHRISTIE + UNIMAN system, the GSI 
system (Figure 6D) holds samples in the horizontal position lifting them to the beam for irradiation. 
This change in orientation minimizes the time that cells are free from media, ensuring a good cellular 
environment and avoiding sample drying. Alternatively, samples can be prepared so that the culture 
vessel is full of cell media, which is the case for RUG (Figure 6B) and Institut Curie (Figure 6C). 
4 Biology – Sample Preparation and Processing 
Alongside the physics capabilities, the biological equipment available at a center will often 
define the type and complexity of experiments that are possible. This impacts both the pre-irradiation 
sample preparation and post-irradiation analysis. For some experiments it is not possible to prepare 
samples prior to transport to the irradiating center. Similarly, it is not always possible to fix samples 
following irradiation ready for transport to the home institute. Table 3 gives details of the in vitro 
biological equipment available at INSPIRE partners. In most cases the equipment detailed in Table 3 
is shared between the INSPIRE partner and other groups at the same institute. Therefore, these details 
should be used as a guide for maximum available equipment. Similarly, extra resources may be 
available at a partner’s sister institute. Researchers requiring the use of any of this equipment should 
discuss their needs with the relevant partner. 
Common amongst all centers is the availability of flow hoods and incubators, with TUD offering 
the largest capacity for sample preparation and storage. At the moment, only one center, UNIMAN, 
has a hypoxia station for irradiation of samples under variable oxygen tension. This offers the capability 
for studying the oxygen enhancement ratio and probing new fields such as the FLASH effect under 
strictly controlled conditions. The hypoxia station at UNIMAN is positioned directly at the beam 
nozzle, which prevents O2 fluctuations in the sample while it is being transported from the laboratory 
to the irradiation facility. Additionally, the irradiation in hypoxic conditions is possible at AU and GSI, 
where the samples can be gassed inside specially designed containers prior the transportation to the 
experimental room. The availability of more sophisticated post-irradiation analysis, such as flow 
cytometry, FACS, mass spectrometry, PCR, and sequencing is varied amongst the partners. Similarly, 
the advanced microscopy available amongst the partners is varied, though the majority have fluorescent 
and confocal microscopes available.
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While all the INSPIRE TNA partners mentioned in this work offer the environment for in vitro 
studies, the in vivo capabilities are slightly more limited, as seen in Figure 2. Despite the data from cell 
experiments being a valuable preliminary tool for studying the effects of proton beams, all of the 
physiological processes and their complex interplay cannot be reproduced in vitro, and thus the clinical 
treatments must first be simulated using animal models before moving onto human trials. Table 4 
shows the in vivo capabilities of the INSPIRE TNA providers. 
In vivo experiments bring the added complexity of ethical review. INSPIRE has a well-
established ethics platform for both its TNA and JRA, which is overseen by an ethics panel comprised 
of international experts in the field. The partners must also follow both the official regulations of their 
country/state as well as those of the TNA provider. Moreover, these regulations might vary from one 
state to another within the same country (for example, in Germany). Ethics applications in EU generally 
require a FELASA (Federation of European Laboratory Animal Science Associations) certification for 
participating scientists that cover the duration of the relevant research. In addition to that, country-
specific licenses might be required. In the latter case, exceptions can be made when the guest scientists 
are only irradiating the animals without leaving them at the TNA facility. The application for the ethical 
approval is normally done well in advance, as the review procedure can last up to several months. All 
of the paperwork relating to ethical approval is retained by the partner and made available to the EU 
upon request. In addition, for some experiments the EU requires copies of the ethical permissions prior 
to any experiment taking place. 
5 Future Perspectives 
As has been shown, the resources available within the INSPIRE network are state-of-the-art. 
Further to this a number of new centers are under development and will soon be accessible to the 
research community. For example, the Proteus ONE IBA center at Charleroi (Belgium) will offer both 
in vitro and in vivo capabilities complete with a basic in vitro lab and animal facility on site, with 
researcher access offered through partnership with Namur. Belgium is also developing a center at 
Leuven, which will also offer in vitro and in vivo research capabilities. Furthermore, the European 
project SEEIST [38,43] will develop capabilities in South-eastern Europe, filling in some geographical 
gaps shown in Figure 1. As well as developing a new heavy ion center the SEEIST project will have 
access to resources provided by INSPIRE. 
 There is a growing European interest into studying the effectiveness of heavy ions, with four 
operational carbon centers and two new centers under construction. A 2019 meeting of UK clinicians, 
scientists, engineers, and stakeholders began the process of considering future UK development of 
heavy ion therapy. There are also ongoing investigations into the clinical utilization of other particle 
types. For example, Helium has been seen as an intermediate between protons and carbon [44–46]. 
Other studies investigate the possibilities of combining multiple beams within one treatment plan to 
ensure a more uniform RBE distribution [47], or better treatment of hypoxic tumors [48]. The INSPIRE 
network is well placed for the associated radiobiological investigations here, in particular with the 
partner institutes GSI and RUG. 
 There has been a worldwide renewed interest in radiotherapy delivery techniques and improved 
normal tissue sparing. For example, spatially fractionated proton therapy [49–52] and ultra-high dose 
rate (FLASH) [53–56]. In these cases, the radiobiological mechanism driving the effect remains 
elusive. In particular, the differences between photon and particle therapy requires further 
investigation. Alongside this, the combination of particle therapy with immunotherapy [57,58] is an 
exciting treatment that requires mechanistic understanding. Again, the INSPIRE network provides 
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resources for investigation here, particularly through in vivo work, with results being directly useful 
for clinical adoption. 
 In vivo radiobiological research is a crucial step along the path to clinical implementation. Eight 
of the 12 partners discussed in this work are currently performing in vivo research. Further to this, 
CHRISTIE + UNIMAN are beginning development of a second beamline for in vivo work. Skandion 
are also in the early stages of planning future in vivo work. This added capacity, and the currently 
available capacity, is sure to aid in the clinical efficacy of proton therapy. 
 The connection between research activities and clinically relevant questions must be made 
stronger. There are close links between many INSPIRE partners and clinical centers, which aids in 
this connection. However, it is important that the clinical community become more involved with 
research at inception. With a limited amount of finances this will ensure prioritization of the most 
pertinent research and advance clinical translation, all for the benefit of the patient. 
6 Conclusion 
In this work we have given details about the radiobiological capabilities of partners involved in 
the INSPIRE project, including how the resources can be accessed. It is clear that whilst there are a 
number of differences between the partners there are also a number of similarities. This allows for 
investigations into the cause of variance in published radiobiological data, such as the planned joint 
experiment of the INSPIRE partners. However, establishing these research centers requires 
significant investment and, as can be seen, many of the capabilities are already in place. More effort 
must be made to develop and utilize the resources currently available to us. Efforts are being made to 
further increase in vivo capabilities, whilst in vitro research is invaluable for identifying and probing 
mechanisms, in vivo research is crucial for clinical adoption. Also required here is a closer 
relationship with clinical partners, ensuring a good direction for future research. With a renewed 
interest in radiotherapy delivery techniques, and the unknown biological mechanisms, now is 
certainly and exciting time for particle radiobiology. Mechanisms that the INSPIRE network is well 
placed to address. 
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Centre Abbreviation Location Website 
Aarhus University AU Aarhus, Denmark 
https://www.en.auh.dk/department
s/the-danish-centre-for-particle-
therapy/ 
The Christie NHS 
Foundation Trust CHRISTIE Manchester, UK https://www.christie.nhs.uk 
GSI Helmholtz Centre 
for Heavy in Research GSI Darmstadt, Germany 
https://www.gsi.de/work/forschung
/biophysik.htm 
 
The Henryk 
Niewodniczański 
Institute of Nuclear 
Physics Polish 
Academy of Sciences 
IFJ PAN Kraków, Poland 
https://inspire.ifj.edu.pl/en/index.p
hp/dostep-do-infrastruktury-
badawczej/ 
Curie Institute Institut Curie Paris, France 
https://institut-
curie.org/page/research-and-
development-proton-therapy-
center 
Nuclear Physics 
Institute of the Czech 
Academy of Sciences 
NPI-CAS Prague, Czech Republic http://www.ujf.cas.cz/en/ 
Paul Scherrer Institute PSI Zurich, Switzerland https://www.psi.ch/en 
University of 
Groningen RUG Groningen, Netherlands 
https://www.rug.nl/kvi-
cart/research/facilities/agor/ 
Skandion Clinic Skandion Uppsala, Sweden https://skandionkliniken.se/ 
Technical University of 
Dresden TUD Dresden, Germany 
https://www.oncoray.de/research/o
ffer-for-users/ 
University Medical 
Center Groningen UMCG Groningen, Netherlands 
https://www.umcgradiotherapie.nl/
en/umc-groningen-department-of-
radiation-oncology 
University of 
Manchester UNIMAN Manchester, UK 
https://www.bmh.manchester.ac.uk
/research/domains/cancer/proton/ 
Table 1: The INSPIRE partners offering equipment and support for radiobiological experiments through transnational 
access. 
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GSI H x ✓ ✓ x ✓ ✓ 
IFJ PAN H ✓ x ✓ ✓ ✓ ✓ 
Institut Curie H + V ✓ ✓ ✓ ✓ ✓ x 
NPI-CAS H + V ✓ x ✓ ✓ ✓ x 
PSI H + V ✓ x ✓ ✓ ✓ ✓ 
RUG + UMCG H x ✓ ✓ ✓ ✓ ✓ 
Skandion H + V ✓ x ✓ ✓ ✓ ✓ 
TUD H x x ✓ ✓ ✓ ✓ 
CHRISTIE + 
UNIMAN H ✓ ✓ ✓ x ✓ ✓ 
Table 2: Beamline and radiobiological sample details of the INSPIRE partners. All centers can offer a horizontal beamline, 
with the four able to irradiate samples from above or at user-defined angles using a gantry. There is flexibility in sample 
types, but the majority of centers have the ability to irradiate flasks and well plates. 
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GSI 2 4 x ✓ ✓ ✓ x ✓ x ✓ ✓ x 
IFJ PAN 2 1 x ✓ x x x ✓ x ✓ ✓ x 
Institut 
Curie 1 1 x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
NPI-CAS 2 3 x ✓ x x x ✓ ✓ ✓ x x 
PSI * 0 1 x x x x x x x x x x 
RUG + 
UMCG 2 2 x ✓ x x x x x x ✓ x 
Skandion 4 4 x ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
TUD 6 12 x ✓ ✓ x x ✓ x ✓ ✓ x 
CHRISTI
E + 
UNIMA
N 
5 5 ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Table 3: In vitro biological analysis equipment available at the INSPIRE partners. *Biological equipment at PSI is available 
at a partner institute and will need to be discussed. 
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PAN 
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Institut 
Curie 
Rats, 
Mice 
100 
Rats, 
40 
Mice 
A few 
months ✓ ✓ 
Normal tissue 
and a range of 
tumor models 
(syngenic and 
xenografts), 
orthotopic 
grafts, specific 
tissue toxicity 
assays 
CT, X-ray, OCT, 
Bioluminescence ✓ 
PSI * 
Mice, 
Zebrafish 
- - ✓ ✓ - - - 
RUG + 
UMCG 
Rats, 
Mice 
132 
Rats, 
264 
Mice 
7 ✓ ✓ Normal tissue ✓ ✓ 
TUD 
Rats, 
Mice, 
Zebrafish 
100 7 ✓ ✓ 
Zebrafish 
embryo strain 
wild type AB; 
NMRI nu/nu 
Nude, 
C57Bl/6JRj 
and 
C3H/HeNRj 
CT, X-ray, MRI, 
Proton 
radiography, 
Bioluminescence, 
PET, Ultrasound 
✓ 
Table 4: In vivo capabilities available at the INSPIRE partners. *In Vivo irradiation at PSI has previously been done, but 
capacities and equipment need to be discussed. 
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Figure 1: European clinical proton therapy centers (closed triangle, 26 centers), carbon therapy centers (closed circle, 4 
centers), and INSPIRE partners offering radiobiological TNA (closed squares, 12 centers – there is some overlap between 
centers). Open symbols show centers currently in the planning stage or under construction. Information is from the PTCOG 
website [1]. 
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Figure 2: INSPIRE partners offering radiobiological investigation with particles. The quoted energies are as extracted from 
the beamlines, lower energies are available with beam degraders. Centers offering both in vitro and in vivo experiments are 
marked with orange circles, while those offering only in vitro experiments are shown as blue squares. 
Figure 3: Proton energies available at INSPIRE partners as extracted from the accelerator. The highest energy is available 
at GSI (up to 4.5 GeV). The lowest energies are available at RUG (15 MeV) and Institut Curie (20 MeV). The overlapping 
region (shaded area) is between 120-190 MeV. Energies can be further degraded in front of the sample. 
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Figure 4: Beamline setup for (A) UNIMAN + CHRISTIE, (B) Skandion, (C) RUG, (D) TUD, (E) GSI, and (F) Institut 
Curie. UNIMAN has a beamline leading to a Varian scanning nozzle, samples are placed in front of the nozzle (pictured is 
a hypoxia cabinet). Skandion has a beamline leading to an IBA scanning nozzle, samples are placed on an adjustable table 
in front of the nozzle. RUG has a flexible beamline setup using optical benches; picture shows a study on the effect of 
magnetic fields in combination to proton irradiation [23]. TUD has two beamlines in the dedicated experimental room, one 
with a pencil beam scanning nozzle (left) and one static beamline (right). In the picture, setups with water tank and beam 
dump at the scanning beamline and passive double scattering setup for radiobiological experiments at the static beamline 
are shown. GSI shows the beamline setup for “Cave A”, equipped with the robotic system for sample exchange. Institut 
Curie shows three irradiation rooms; “Room Y1” – horizontal beam up to 201 MeV (left), “Room Y2” – horizontal beam 
up to 76 MeV (right), and “IBA Room” – gantry up to 230 MeV (bottom). 
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Figure 5: Maximum available scanned field sizes of the INSPIRE partners, ranging from 10 × 10 cm2 to 30 × 40 cm2. 
Larger field sizes may be available by introducing scatterers. 
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Figure 6: Setup for sample irradiation at (A) 
CHRISTIE + UNIMAN, (B) RUG, (C) Institut Curie, (D) GSI, and (E) AU. The CHRISTIE + UNIMAN system is a 6-
axis robotic arm mounted in a hypoxia cabinet, allowing irradiation at different oxygen tensions from 0.1-20%. The robot 
picks samples from a “hotel” and holds them in front of a beam window within the cabinet, before either replacing the 
sample to the hotel or moving to an automated fixation system (left). The hotel can house up to 36 samples, a mix of T75 
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flasks or 96-well plates (right). The RUG system shows the sequential irradiation of three 12-well plates. Wells are filled 
with cell media and sealed with parafilm. The Institut Curie system shows sequential irradiation of six in vitro samples 
(left), and immobilized in vivo irradiation (right). The GSI system allows for sequential irradiation of 16 tissue culture 
flasks. The flasks remain in the horizontal position whilst not being irradiated (left), preventing the cell layer inside from 
drying. The robotic system lifts the sample and presents it to the beam (right), replacing it when irradiation is complete. 
The AU system shows an in vivo setup for mouse leg irradiation. 
 
